Basis: FMP quote price / unrounded diluted EPS from four consecutive issuer fiscal quarters. Source: stored company filings and market data; unavailable inputs remain N/A.
The P/E ratio is N/A as of 2026-10-06T17:36:22.153Z.
Calculation as of: 2026-10-06T17:36:22.153Z.
Quote observation: 2026-10-06T17:35:15.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: f97479f440d7a03605f533a56e26179237db48e588053495707f458dff3bcd44
PE RATIO
N/A
Market Cap
$5.07B
PE Ratio
35.05
TTM Avg
36.67
3Y Avg
43.17
5Y Avg
53.01
Market Cap
$4.68B
PE Ratio
92.95
TTM Avg
202.48
3Y Avg
202.48
5Y Avg
202.48
| NAME | MARKET CAP | PE RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Erasca, Inc. (ERAS) | $4.97B | N/A | N/A | N/A | N/A |
| Scholar Rock Holding Corporation (SRRK)vs › | $5.05B | N/A | N/A | N/A | N/A |
| Merit Medical Systems, Inc. (MMSI)vs › | $5.07B | 35.05 | 36.67 | 43.17 | 53.01 |
| Mirum Pharmaceuticals, Inc. (MIRM)vs › | $4.81B | N/A | N/A | N/A | N/A |
| Travere Therapeutics, Inc. (TVTX)vs › | $5.14B | N/A | N/A | N/A | N/A |
| Oruka Therapeutics, Inc. (ORKA)vs › | $4.76B | N/A | N/A | N/A | N/A |
| Cogent Biosciences, Inc. (COGT)vs › | $5.18B | N/A | N/A | N/A | N/A |
| CRISPR Therapeutics AG (CRSP)vs › | $5.23B | N/A | 17.47 | 59.21 | 59.21 |
| LifeStance Health Group, Inc. (LFST)vs › | $4.68B | 92.95 | 202.48 | 202.48 | 202.48 |
| BillionToOne, Inc. (BLLN)vs › | $4.66B | 163.47 | 879.32 | 879.32 | 879.32 |
Trailing P/E
N/A
Forward P/E
N/A
Forward P/E is calculated using analyst consensus EPS estimates for the current or next fiscal year.
Calculation:
Current Price
$14.32
Forward EPS (Est.)
$-0.97
Forward P/E
N/A
Source: FMP Analyst Consensus Estimates. Forward EPS represents the average analyst estimate for the nearest fiscal year.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
